Showing 2091-2100 of 2192 results for "".
- OnabotulinumtoxinA Approved for Treatment of Children with Upper Limb Spasticityhttps://practicalneurology.com/news/onabotulinumtoxina-approved-for-treatment-of-children-with-upper-limb-spasticity/2468936/The Food and Drug Administration (FDA) has approved a new indication for onabotulinumtoxinA (Botox; Allergan, Madison, NJ)—treatment of upper limb spasticity in children, age 2 to 17 years. The decision came after a 6-month priority review, which istypically granted to therapies with potent
- Phase 2 Study of Potential Acute Ischemic Stroke Treatment Planned for 2019https://practicalneurology.com/news/phase-2-study-of-potential-acute-ischemic-stroke-treatment-planned-for-2019/2468930/A phase 2 proof-of-concept study will begin in the US later this year for LT3001 (Lumosa Therapeutics, Taipei, Taiwan), a novel therapy for treating acute ischemic stroke (AIS). Enrollment of participants for the phase 2 study in Taiwan will begin in 2020. Full enrollment is expected to take 2 ye
- Funding Provided for Project to Involve People with Dementia in Researchhttps://practicalneurology.com/news/funding-provided-for-project-to-involve-people-with-dementia-in-research/2468929/LiveWell Dementia Specialists in Plantsville, CT has received $250,000 in funding for a 2-year project to engage people with dementia as research partners. The first of its kind, the Empowering Partnerships project aims to enhance research by developing a network of people with dementia, family c
- Phase 2b Study Ending for Sublingual Ketamine for Acute Painhttps://practicalneurology.com/news/phase-2b-study-ending-for-sublingual-ketamine-for-acute-pain/2468909/The Food and Drug Administration (FDA) has scheduled an end-of-phase 2 clinical trial meeting for a sublingual formulation of racemic ketamine (Wafermine; iX Biopharma, Singapore) for treatment of moderate-to-severe acute pain. The therapy contains R and S isomers of ketamine in e
- Novel Therapy for Alzheimer’s Disease Receives NIA Supporthttps://practicalneurology.com/news/novel-therapy-for-alzheimers-disease-receives-nia-support/2468907/The National Institute on Aging (NIA) has provided a 4-year grant for a phase 2 study of T3D-959 (T3D Therapeutics, Research Triangle Park, NC), a novel, metabolic-focused treatment for Alzheimer’s disease (AD). The PIONEER study, which will begin patient dosing in ear
- Zolgensma—Gene Replacement Therapy—for Treatment of Spinal Muscular Atrophyhttps://practicalneurology.com/news/zolgensmagene-replacement-therapyfor-treatment-of-spinal-muscular-atrophy/2468902/Results from multiple trials of SMN1gene-replacement therapy (Zolgensma; Avexis, Bannockburn, IL) show promise for single-dose treatment of spinal muscular atrophy (SMA). In the STRIVE phase 3 study for treatment of spinal muscular atrophy, 22 infants under age 6 months, diag
- Tofersen for Treatment of Familial Amyotrophic Lateral Sclerosishttps://practicalneurology.com/news/experimental-drug-shows-promise-for-treating-genetic-form-of-als/2468879/An early-stage trial for tofersen (BIIB067; Biogen, Cambridge, MA) an investigational drug for amyotrophic lateral sclerosis (ALS), showed that the drug is linked to slower progression of a form of the disease caused by mutations in the superoxide dismutase 1 (SOD1) gene. Results of the stud
- Humanized Antibody Targets Tau Protein in Alzheimer's Diseasehttps://practicalneurology.com/news/humanized-antibody-targets-tau-protein-in-alzheimers-disease/2468881/A Harvard Medical School study demonstrates that a humanized monoclonal antibody (TBL-100; TAU BIOLOGIC Corporation, New York, NY) targets C-terminally truncated tau (tauC3) for the treatment of Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP).
- Nusinersen Efficacy for Later-Onset Spinal Muscular Atrophy Types II and IIIhttps://practicalneurology.com/news/nusinersen-efficacy-for-later-onset-spinal-muscular-atrophy-types-ii-and-iii/2468883/April 24, 2019—Children with later-onset spinal muscular atrophy (SMA) types II and III treated with nusinersen (Spinraza; Biogen, Cambridge MA) had motor function improvement and disease stabilization over a 3-year period. Of the children with SMA II, 78% (7 of 9) had clinically meaningful
- Analysis of Cladribine Tablets Clinical Trials Continues to Support Safety and Efficacyhttps://practicalneurology.com/news/analysis-of-cladribine-tablets-clinical-trials-continues-to-support-safety-and-efficacy/2468807/In the 2-year CLARITY trial (NCT00213135), 47% of patients treated with cladribine tablets (CT) (EMD Serono; Rockland, MA) achieved no evidence of disease activity (NEDA) compared with 17% of patients treated with placebo (P <